Aug 5, 2026 · 7 min
Novo Nordisk stumbles as AI valuation fears hit European stocks
Novo Nordisk Drops, Next Jumps, Infineon Falls
The episode shows how drug demand, retail momentum and skepticism about AI valuations are pulling European market leaders in different directions.
- 1Wegovy sales disappointed investors who had set exceptionally high expectations for Novo Nordisk.
- 2Next raised its guidance for the third time this fiscal year as warm weather and international performance supported its shares.
- 3Infineon's strong data-center-driven results failed to overcome investor anxiety about elevated AI sector valuations.
Don't miss
Infineon's strong data-center results still failed to reassure investors worried that AI-related valuations had become too high.
The brief
Bloomberg reporters Tiwa Adebayo and Caroline Hepker introduce Chloe Melley to examine the European stocks moving on earnings, guidance and shifting investor expectations.
Novo Nordisk shares fell after Wegovy sales failed to meet the lofty expectations surrounding its highly anticipated weight-loss treatment, putting investor enthusiasm under pressure.
UK retailer Next moved higher after raising guidance for the third time this fiscal year, with warm weather and strong international performance supporting the outlook.
Infineon reported strong results driven by data-center demand, but its shares declined as investors remained uneasy about high valuations across the AI sector.
Together, the moves show markets separating business strength from valuation risk: solid results can still disappoint when expectations have already run ahead.
What was said on this episode
12 statements · 4 positive · 5 negative · 2 mixed · 1 neutral
Wegovy sales disappointed investors by failing to meet expectations.
“the sales of its weight loss pill disappointed investors”
Listen at 1:14
Several factors may complicate Novo Nordisk’s outlook.
“there's going to be some, perhaps some things kind of complicating the outlook for Novo”
Listen at 1:42
Eli Lilly’s weight-loss pill may affect Novo Nordisk’s outlook.
“there's the question as well of how successful Eli Lilly is going to be with its own weight loss pill that it has”
Listen at 1:59
Novo Nordisk has experienced recent clinical-trial setbacks.
“there's been recent trial setbacks as well for Novo”
Listen at 2:07
Eli Lilly and Novo Nordisk continue competing in weight-loss drugs.
“there's this continued competition between Eli Lilly and Novo Nordisk”
Listen at 2:10
Next is a bright spot in the UK retail sector.
“NEXT is really kind of confirming its status as a really bright spot in that UK retail sector”
Listen at 2:53
Next raised its guidance for the third time this fiscal year.
“NEXT this morning boosted its guidance for the third time this fiscal year”
Listen at 3:05
Next’s international division performed strongly.
“its international division also performed very well”
Listen at 3:17
Next’s update reassured investors about broader retail spending.
“this was probably seen as quite a reassuring update in terms of that broader retail spending”
Listen at 3:38
Infineon delivered strong results that were insufficient for market expectations.
“this is for advine and really a classic story of very strong results, but then just not quite strong enough for this trade”
Listen at 4:11
AI-sector spending may not be sustainable.
“There's a persistent worry around whether this spending in AI is sustainable”
Listen at 4:33
The justification for circular financing in AI remains uncertain.
“whether this circular financing that we're seeing in the sector is justified”
Listen at 4:39
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.
Featuring
Novo Nordisk
Wegovy
Artificial IntelligenceListen to the full episode and explore every guest, topic, and moment on PodLume.